Title
Pharmacological Management of Irritable Bowel Syndrome
Authoring Organization
Publication Month/Year
November 2, 2014
Last Updated Month/Year
November 6, 2024
Supplemental Implementation Tools
Document Type
Guideline
External Publication Status
Published
Country of Publication
US
Document Objectives
This document presents the official recommendations of the American Gastroenterological Association (AGA) on the use of pharmacological agents for the treatment of irritable bowel syndrome (IBS) in adults.
Target Patient Population
Adults with irritable bowel syndrome (IBS)
PICO Questions
Should Linaclotide Be Used in Patients With IBS-C?
Should Lubiprostone Be Used in Patients With IBS-C?
Should PEG Laxatives Be Used in Patients With IBS-C?
Should Rifaximin Be Used in Patients With IBS-D?
Should Alosetron Be Used in Patients With IBS-D?
Should Loperamide Be Used in Patients With IBS-D?
Should Tricyclic Antidepressants Be Used in Patients With IBS?
Should Selective Serotonin Reuptake Inhibitors Be Used in Patients With IBS?
Should Antispasmodics Be Used in Patients With IBS?
Inclusion Criteria
Male, Female, Adult, Older adult
Health Care Settings
Ambulatory
Intended Users
Nurse, nurse practitioner, physician, physician assistant
Scope
Treatment, Management
Diseases/Conditions (MeSH)
D043183 - Irritable Bowel Syndrome
Keywords
irritable bowel syndrome (IBS), IBS-D, IBS, IBS-C, irritable bowel syndrome with diarrhea, irritable bowel syndrome with constipation
Source Citation
Weinberg DS, Smalley W, Heidelbaugh JJ, Sultan S. American Gastroenterological Association Institute Guideline on the Pharmacological Management of Irritable Bowel Syndrome. Gastroenterology 2014;147:1146–1148.